CONCORD BIOTECH LIMITED

CONCORD BIOTECH LIMITED is a prominent Indian biopharmaceutical company. It is primarily engaged in the research, development, manufacturing, and marketing of fermentation-based active pharmaceutical ingredients (APIs) and finished formulations. The company has a strong presence in various therapeutic areas including immunosuppressants, oncology, anti-infectives, and nephrology. Known for its robust manufacturing infrastructure and significant investment in research and development, Concord Biotech has established itself as a key player in the global biopharmaceutical industry.

The company is a factory.

Concord Biotech Limited manufactures and sells a range of biopharmaceutical products. These primarily include immunosuppressants such as Mycophenolate Mofetil, Tacrolimus, Sirolimus, and Cyclosporine. Their product portfolio also encompasses anti-infectives and antifungals like Rifampicin, Caspofungin Acetate, Micafungin Sodium, Anidulafungin, Voriconazole, and Posaconazole. Additionally, the company produces oncology-related active pharmaceutical ingredients (APIs) including Everolimus and Temsirolimus, along with other specialized APIs and finished dosage forms such as Eptifibatide, Daptomycin, and Linezolid.